Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2007

01-08-2007 | Abstract

Revised Abstracts San Antonio Breast Cancer Symposium 2006

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access

Excerpt

Background: The third-generation, non-steroidal aromatase inhibitors (AIs; anastrozole and letrozole) are increasingly used as adjuvant and first-line advanced treatments for postmenopausal women with hormone receptor-positive (HR+) breast cancer. As many patients subsequently progress or relapse, it is important to identify agents with efficacy following AI failure. …
Metadata
Title
Revised Abstracts San Antonio Breast Cancer Symposium 2006
Publication date
01-08-2007
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9661-1

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Clinical Trial

A cognitive behavioral therapy intervention to promote weight loss improves body composition and blood lipid profiles among overweight breast cancer survivors

Review Paper

The role of ATM in breast cancer development

Review Paper

Identifying menopause in breast cancer patients: considerations and implications

Epidemiology

MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling

Clinical Trial

Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers

OriginalPaper

MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits